Adverse Outcomes Associated With Interleukin-6 in Patients Recently Hospitalized for Heart Failure With Preserved Ejection Fraction

Abstract

Background: Inflammation may play a role in the pathophysiology of heart failure with preserved ejection fraction. We examined whether circulating levels of interleukin-6 identify patients at greater risk of adverse outcomes following hospitalization with heart failure with preserved ejection fraction. Methods: We assessed relationships between interleukin-6 (IL-6) tertiles (T1-3) and all-cause death, cardiovascular death, and subsequent heart failure hospitalization (sHFH) in 286 patients recently hospitalized with heart failure with preserved ejection fraction. Associations between IL (interleukin)-6 and outcomes were examined in a Cox-regression model adjusted for risk factors including BNP (B-type natriuretic peptide). Biomarkers including hsCRP (high-sensitivity C-reactive protein) were assessed. Results: The range of IL-6 (pg/mL) in each tertile was T1 (0.71–4.16), T2 (4.20–7.84), and T3 (7.9–236.32). Compared with T1, patients in the highest IL-6 tertile were more commonly male (56% versus 35%) and had higher creatinine (117±45 versus 101±36 μmol/L), hsCRP (11.6 [4.9–26.6]mg/L versus 2.3[1.1–4.2] mg/L). In univariable analysis, rates of all-cause death, cardiovascular death, and sHFH were higher in T3 versus T1. All-cause and cardiovascular death rates remained higher in T3 versus T1 after adjustment ( P <0.001). One log unit increase in IL-6 was associated with higher risk of all-cause death (hazard ratio, 1.46 [1.17–1.81]), cardiovascular death (hazard ratio, 1.40 [1.10–1.77]), and sHFH (hazard ratio, 1.24 [1.01–1.51]) after adjustment. One log unit increase in hsCRP was associated with a higher risk of cardiovascular death and all-cause death before and after adjustment for other factors but was not associated with risk of sHFH before or after adjustment. Conclusions: In patients recently hospitalized with heart failure with preserved ejection fraction, IL-6 is an independent predictor of all-cause mortality, cardiovascular death, and sHFH after adjustment for risk factors including BNP. These findings are of particular relevance in the context of current anti–IL-6 drug development.

The sGCa Vericiguat Exhibit Cardioprotective and Anti-Sarcopenic Effects through NLRP-3 Pathways: Potential Benefits for Anthracycline-Treated Cancer Patients

“…We found that vericiguat is able to change the intracellular cytokine composition in skeletal muscle cells and cardiomyocytes exposed to doxorubicin (Figure 5), inducing an anti-inflammatory phenotype. Myocardial and skeletal muscle cells with high levels of IL-1 and IL-6 are exposed to a greater risk of heart attack and rupture of myofibrils, respectively [69]. Recent clinical work associates high plasma levels of chemokine ligand 2 (CXCL2) with chronic heart failure and sarcopenia [70].…”

It’s Not You, It’s Me: Uncovering Heart-Kidney Relationship Failures

“…Both are associated with incident HFpEF in population studies and are highly prognostic in patients hospitalized for HFpEF. 6,7 GDF-15 promotes weight loss, modulates macrophage phenotypes, and may represent a homeostatic response to inflammation; GDF-15 inhibition is not yet an obvious approach for HF prevention. In contrast, a large clinical trial (ZEUS [A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease, and Inflammation]: NCT05021835) is testing whether the monoclonal IL-6 antibody ziltivekimab reduces cardiovascular events (including, as a secondary end point, HF hospitalizations) in patients with CKD.…”

Early Appearance of Myocardial Fibrosis in Restrictive Diabetic Cardiomyopathy

“…16 In line with IL-1 blockade, IL-6 blockade (eg, with the monoclonal antibody tocilizumab) deserves to be evaluated because patients with HFpEF with high IL-6 were recently demonstrated to have both worse exercise hemodynamics and poor outcome. 17 Inhibition of myeloperoxidase which is abundantly present in neutrophile granulocytes, is also being evaluated. Preliminary findings are encouraging as a 3-month treatment period with the myeloperoxidase inhibitor AZD4831 downregulated expression of plasma biomarker pathways observed in poor outcome HFpEF.…”